NCT06091943 - Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Tislelizumab IV

Planned doses will be administered intravenously.

DRUG

Tislelizumab SC

Planned doses will be administered via subcutaneous injection.

DRUG

Histology-Based Chemotherapy Doublet

"Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."

Trial Locations (15)

2025

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

250117

Shandong Cancer Hospital, Jinan

272002

Jining No Peoples Hospital East Branch, Jining

313003

Huzhou Central Hospital, Huzhou

330006

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

350014

Fujian Cancer Hospital, Fuzhou

350025

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

450000

Henan Cancer Hospital, Zhengzhou

618000

Deyangs People Hospital, Deyang

030013

Shanxi Provincial Cancer Hospital, Taiyuan

030032

Shanxi Bethune Hospital, Taiyuan

0112

Arensia Exploratory Medicine Llc, Tbilisi